• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Laboratoires Thea acquires insert from Carl Zeiss Meditec

Article

Laboratoires Thea has acquired from Carl Zeiss Meditec a mydriatic ophthalmic insert (Mydriasert) indicated for dilated fundus examination or cataract surgery.

Clermont-Ferrand, France-Laboratoires Thea has acquired from Carl Zeiss Meditec a mydriatic ophthalmic insert (Mydriasert) indicated for dilated fundus examination or cataract surgery.

The agreement includes the acquisition of the production site of the insert in La Rochelle, France, along with relevant staff.

“This acquisition represents a significant addition to our product range and is completely in line with our strategy to become a leading provider of ophthalmic products,” said Jean-Frederic Chibret, Laboratoires Thea chief operating officer.

This device, shaped like an oblong tablet, is applied beneath the eyelid and disperses phenylephrine hydrochloride and tropicamide. The alpha-sympathomimetic activity of phenylephrine induces an increase in pupil diameter, and the anti-cholinergic activity of tropicamide prevents the iris from contracting, according to the company.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.